

1 **Early signals of significantly increased vaccine**
2 **breakthrough, decreased hospitalization rates, and less**
3 **severe disease in patients with COVID-19 caused by the**
4 **Omicron variant of SARS-CoV-2 in Houston, Texas**

5
6
7 Paul A. Christensen,^{*,†,‡,§} Randall J. Olsen,^{*,†,‡,§} S. Wesley Long,^{*,†,‡,§} Richard Snehal,[†]
8 James J. Davis,^{¶,**} Matthew Ojeda Saavedra,[†] Kristina Reppond,[†] Madison N. Shyer,[†]
9 Jessica Cambric,[†] Ryan Gadd,[†] Rashi M. Thakur,[†] Akanksha Batajoo,[†] Regan
10 Mangham,[†] Sindy Pena,[†] Trina Trinh,[†] Jacob C. Kinskey,[†] Guy Williams,[†] Robert
11 Olson,^{¶,**} Jimmy Gollihar,[‡] James M. Musser^{†,‡,§,††}

12
13 **Contributed equally;*

14 *†Laboratory of Human Molecular and Translational Human Infectious Diseases and*

15 *‡Laboratory of Antibody Discovery and Accelerated Protein Therapeutics, Center for*

16 *Infectious Diseases, Houston Methodist Research Institute and Department of*

17 *Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas;*

18 *§Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New*

19 *York, New York;*

20 *¶Consortium for Advanced Science and Engineering, University of Chicago, Chicago,*

21 *Illinois;*

22 *** Computing, Environment and Life Sciences, Argonne National Laboratory, Lemont,*
23 *Illinois;*

24

25 *†† Address correspondence to James M. Musser, M.D., Ph.D., Department of Pathology*
26 *and Genomic Medicine, Houston Methodist Research Institute, 6565 Fannin Street,*
27 *Suite B490, Houston, Texas 77030. Tel: 713.441.5890, E-mail:*

28 jmmusser@houstonmethodist.org

29

30 Running head: Omicron variant in Houston, Texas

31

32 Disclosures: None.

33

34 Funding: This project was supported by the Houston Methodist Academic Institute
35 Infectious Diseases Fund; and in part with funds from the National Institute of Allergy
36 and Infectious Diseases, National Institutes of Health, Department of Health and Human
37 Services, under Contract No. 75N93019C00076 (J.J.D.).

38

39

40 **Abstract**

41 Genetic variants of SARS-CoV-2 continue to dramatically alter the landscape of the
42 COVID-19 pandemic. The recently described variant of concern designated Omicron
43 (B.1.1.529) has rapidly spread worldwide and is now responsible for the majority of
44 COVID-19 cases in many countries. Because Omicron was recognized very recently,
45 many knowledge gaps exist about its epidemiology and clinical severity and disease
46 course. A comprehensive genome sequencing study of SARS-CoV-2 in the Houston
47 Methodist healthcare system identified 862 symptomatic patients with infections caused
48 by Omicron from late November 2021 through December 18, 2021. Omicron very
49 rapidly increased in only three weeks to cause 90% of all new COVID-19 cases.
50 Compared to patients infected with either Alpha or Delta variants in our healthcare
51 system, Omicron patients were significantly younger, had significantly increased
52 vaccine breakthrough rates, and were significantly less likely to be hospitalized.
53 Omicron patients required less intense respiratory support and had a shorter length of
54 hospital stay, consistent with decreased disease severity. Although the number of
55 Omicron patients we studied is relatively small, in the aggregate the data document the
56 unusually rapid spread and increased occurrence of COVID-19 caused by the Omicron
57 variant in metropolitan Houston, and provide information about disease character.

58

59

60

61 [Introduction]

62

63

64 Over the last 14 months, the Alpha and Delta variants of concern (VOCs) of SARS-

65 CoV-2 have caused two distinct COVID-19 disease surges in the United States,

66 Southeast Asia, Europe, and elsewhere ([https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html)

67 [ncov/cases-updates/variant-surveillance/variant-info.html](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html)), last accessed December 30,

68 2021; <https://www.gov.uk/government/collections/new-sars-cov-2-variant>, last accessed

69 December 30, 2021)¹, and remodeled the landscape of human behavior and many

70 societies. Delta replaced the Alpha variant as the cause of virtually all COVID-19 in

71 many countries ([https://www.who.int/publications/m/item/weekly-epidemiological-](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021)

72 [update-on-covid-19---13-july-2021](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021), last accessed August 18, 2021;

73 <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditions>

74 [anddiseases/bulletins/coronaviruscovid19infectionsurveyspilot/9july2021](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditions), last accessed

75 August 18, 2021).

76 At the start of the pandemic almost two years ago, the Houston Methodist

77 healthcare system instituted a comprehensive and integrated population genomics

78 project designed to sequence all SARS-CoV-2 samples causing COVID-19 in patients

79 cared for at our facilities, which include eight hospitals located throughout the

80 metroplex. The project was implemented when the initial Houston Methodist COVID-19

81 case was diagnosed at the end of February 2020, and has continued unabated²⁻⁶. This

82 project was facilitated by the existence of a single large diagnostic laboratory that

83 serves the entire system and is seamlessly integrated with a research institute with

84 extensive genomics expertise and capacity. A key goal was to comprehensively map

85 the population genomics, trajectory, and other features of the pandemic in metropolitan

86 Houston with a population size of approximately 7.2 million. Houston is the fourth
87 largest city in the United States, the most ethnically diverse metropolitan area in the
88 country, and is a major port of entry. To date, SARS-CoV-2 genomes have been
89 sequenced from greater than 70,000 patient samples. Many features of four distinct
90 SARS-CoV-2 waves in Houston have been described²⁻⁶.

91 The successes of rapid SARS-CoV-2 vaccine development and documented
92 efficacy, coupled with the significant downturn of the disease wave caused by Delta in
93 Houston and elsewhere in fall, 2021⁶, suggested that the pandemic was abating.
94 However, the identification of a new VOC designated B.1.1.529 and commonly known
95 as Omicron that has spread rapidly in South Africa and the UK has tempered this
96 optimism⁷⁻⁹. Inasmuch as Omicron was recognized very recently, and much is not
97 known about its epidemiology and clinical characteristics and course, we used our
98 integrated infrastructure in an effort to address some pertinent knowledge gaps.
99 Genome sequencing identified 862 COVID-19 patients with disease caused by Omicron
100 in the Houston Methodist healthcare system beginning in late November 2021 and
101 ending December 18, 2021. In three weeks Omicron spread throughout the Houston
102 metropolitan region and became the cause of 90% of new COVID-19 cases. Although
103 the number of our Omicron patients is relatively small, compared to patients infected
104 with either Alpha or Delta variants and cared for in our system, significantly fewer
105 Omicron patients were hospitalized, and those who were hospitalized required
106 significantly less intense respiratory support and had a shorter length of stay. We
107 cautiously interpret our findings to be consistent with decreased disease severity among
108 Houston Methodist Omicron patients. Many factors undoubtedly have contributed,

109 including but not limited to increased vaccination uptake, population immunity, and
110 patient demographics such as younger age. The extent to which our findings translate
111 to other cities and other patient populations, including children, is unknown. Our study
112 was not designed to address possible intrinsic differences in virulence of Omicron
113 compared to Alpha, Delta, and other VOCs. We believe this topic remains an open
114 question that warrants further investigation.

115

116

117 **Materials and Methods**

118

119 **Patient Specimens**

120

121 Specimens were obtained from patients registered at Houston Methodist facilities (e.g.,
122 hospitals and urgent care centers), and institutions in the Houston metropolitan region
123 that use our laboratory services. The great majority of individuals had signs or
124 symptoms consistent with COVID-19 disease. For analyses focusing on patients with
125 COVID-19 caused by the Omicron variant, samples obtained from November 27, 2021
126 through December 18, 2021 were used. This time frame was chosen because it
127 represents the period during which an Omicron variant was first identified in our
128 healthcare system and the last date of specimen collection used to generate genome
129 sequence data for this manuscript. For analyses comparing features of patients infected
130 with the Omicron VOC and Alpha and Delta VOCs, all patients documented to be

131 infected with these variants in the Houston Methodist system were studied. The study
132 included 36,164 unique patients identified in this time frame for whom we had SARS-
133 CoV-2 genome sequences. The work was approved by the Houston Methodist
134 Research Institute Institutional Review Board (IRB1010-0199).

135

136 SARS-CoV-2 Molecular Diagnostic Testing

137

138 Specimens obtained from symptomatic patients with a suspicion for COVID-19 disease
139 were tested in the Molecular Diagnostics Laboratory at Houston Methodist Hospital
140 using assays granted Emergency Use Authorization (EUA) from the FDA

141 ([https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-
142 diagnostic-testing-sars-cov-2#offeringtests](https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-diagnostic-testing-sars-cov-2#offeringtests), last accessed June 7, 2021). Multiple

143 molecular testing platforms were used, including the COVID-19 test or RP2.1 test with

144 BioFire Film Array instruments, the Xpert Xpress SARS-CoV-2 test using Cepheid

145 GeneXpert Infinity or Cepheid GeneXpert Xpress IV instruments, the Cobas SARS-

146 CoV-2 & Influenza A/B Assay using the Roche Liat system, the SARS-CoV-2 Assay

147 using the Hologic Panther instrument, the Aptima SARS-CoV-2 Assay using the Hologic

148 Panther Fusion system, the Cobas SARS-CoV-2 test using the Roche 6800 system,

149 and the SARS-CoV-2 assay using Abbott Alinity m instruments. Virtually all tests were

150 performed on material obtained from nasopharyngeal swabs immersed in universal

151 transport media (UTM); oropharyngeal or nasal swabs, bronchoalveolar lavage fluid, or

152 sputum treated with dithiothreitol (DTT) were sometimes used. Standardized specimen

153 collection methods were used (<https://vimeo.com/396996468/2228335d56>, last
154 accessed June 7, 2021).

155
156 SARS-CoV-2 Genome Sequencing, Genome Analysis, and Identification of
157 Variants

158
159 We sequenced the SARS-CoV-2 genome of >90% of all positive cases in the Houston
160 Methodist healthcare system during the period studied. Libraries for whole SARS-CoV-2
161 genome sequencing were prepared according to version 4
162 (<https://community.artic.network/t/sars-cov-2-version-4-scheme-release/312>, last
163 accessed August 19, 2021) of the ARTIC nCoV-2019 sequencing protocol. The semi-
164 automated workflow used has been described previously²⁻⁶. Sequence reads were
165 generated with an Illumina NovaSeq 6000 instrument.

166 Viral genomes were assembled with the BV-BRC SARS-Cov2 assembly service
167 (<https://www.bv-brc.org/app/ComprehensiveSARS2Analysis>, last accessed June 7,
168 2021, requires registration). The pipeline currently uses seqtk version 1.3-r117 for
169 sequence trimming (<https://github.com/lh3/seqtk.git>) and minimap version 2.17 for
170 aligning reads against the Wuhan-Hu-1 (NC_045512.2) reference genome. Samtools
171 version 1.11 was used for sequence and file manipulation, where maximum depth and
172 minimum depth parameters in mpileup were set to 8,000 and 3, respectively. iVar
173 version 1.3.1 was used for primer trimming and variant calling. Genetic lineages,
174 VOCs, and variants of interest (VOIs) were identified based on genome sequence data
175 and designated by Pangolin v. 3.1.17 with pangoLEARN module 2021-12-06

176 (<https://cov-lineages.org/resources/pangolin.html>, last accessed December 12, 2021).

177 Genome data used in this study have been deposited to GISAID www.gisaid.org.

178

179 S-Gene Target-Failure Assay

180

181 An S-gene target-failure (SGTF) assay (TaqPath COVID-19 Combo Kit Thermo Fisher,
182 Inc.), was used as a surrogate marker for the Omicron VOC for some specimens
183 collected between December 18, 2021 and December 22, 2021. From November 1,
184 2021 onward, only Delta and Omicron were circulating in metropolitan Houston, as
185 documented by whole-genome sequence data. Thus, samples with S-gene target failure
186 were classified as Omicron, whereas samples yielding amplification of the S-gene were
187 classified as a Delta variant.

188

189 Patient Metadata and Geospatial Analysis

190

191 Patient metadata were acquired from the electronic medical record by standard
192 informatics methods. Figures showing geospatial distribution of spread for Omicron
193 were generated with Tableau version 2021.2.7 (Tableau Software, LLC, Seattle, WA)
194 using patient home address zip codes. A vaccination breakthrough case was defined as
195 a PCR-positive sample from a patient obtained greater than 14 days after full
196 vaccination (e.g., both doses of the Pfizer or Moderna mRNA vaccines) was completed.
197 A booster vaccination breakthrough case was defined as a PCR-positive sample from a
198 patient obtained greater than 14 days after receiving a third vaccine dose. For some

199 cases, manual chart review was conducted to resolve discrepancies or clarify
200 ambiguities.

201

202

203 **Results**

204

205 **Omicron Epidemiologic Wave**

206

207 The first Houston Methodist patient infected with an Omicron variant was identified at
208 the end of November 2021, a time when the Delta VOC was responsible for all COVID-
209 19 cases in metropolitan Houston⁶. During this period, the metropolitan area was
210 experiencing a steady decrease in total number of new COVID-19 cases (**Figure 1**,
211 **Figure 2**).

212 Omicron increased in frequency unusually rapidly over a three-week period in
213 December (**Figure 1**, **Figure 2**). By December 18, the genome sequence data showed
214 that Omicron accounted for 90% of all new COVID-19 cases in our healthcare system
215 (**Figure 2**). This represents the fifth wave of COVID-19 cases in metropolitan Houston
216 (**Figure 1**). The estimated case doubling time during this three-week period was
217 approximately 2.2 days (**Figure 2**), which means that Omicron increased in frequency
218 approximately three times faster than Delta had increased in our area⁶, an
219 unprecedented trajectory for SARS-COV-2 infections.

220 Consistent with extensive infections caused by Omicron in southern Africa and
221 elsewhere (<https://www.cdc.gov/coronavirus/2019-ncov/variants/variant->

222 [classifications.html](#), last accessed December 28, 2021;
223 <https://www.gov.uk/government/collections/new-sars-cov-2-variant>, last accessed
224 December 28, 2021), several patients had very recent travel histories to countries with a
225 high prevalence of this VOC, suggesting acquisition of virus by some cases from abroad
226 and importation into Houston. However, the great majority of Omicron patients had no
227 documented travel outside the US and undoubtedly acquired the infection domestically,
228 either in Houston or elsewhere.

229 To understand the geospatial distribution of Omicron in metropolitan Houston,
230 patient metadata were acquired from the electronic medical record by standard
231 informatics methods, and home address zip codes were used to visualize virus spread
232 (**Figure 2**). The 862 Houston Methodist patients infected with Omicron during this
233 period were distributed widely throughout metropolitan Houston, with 176 different zip
234 codes represented (**Figure 2**). The widespread distribution of Omicron in the Houston
235 metroplex in an extremely short period of time reflects the ability of this variant to spread
236 unusually rapidly and effectively between individuals, and cause symptomatic disease.

237

238 Comparison of Omicron, Alpha, and Delta COVID-19 Cases

239

240 There is a considerable lack of detailed information about patients in the United States
241 and elsewhere with COVID-19 caused by the Omicron VOC. We compared available
242 metadata for all Houston Methodist patients infected with Omicron, Alpha, and Delta
243 VOCs (**Table 1, Table 2**). The populations differed significantly in many characteristics,

244 including median age, hospital admission rates, maximum respiratory support, rate of
245 vaccine breakthrough, and median length of stay (**Table 1, Table 2**).

246 Patients infected with Omicron were significantly younger than Alpha and Delta
247 patients (**Table 1, Table 2**). Importantly, Omicron patients were hospitalized significantly
248 less frequently than patients infected with either the Alpha or Delta variants, and had a
249 significantly shorter median hospital length of stay (**Table 1, Table 2**).

250 We next analyzed Omicron vaccine breakthrough cases (**Table 1, Table 2**). We
251 found 430 of the 862 total Omicron patients (49.9%) for whom we have whole genome
252 sequence data met the CDC definition of vaccine breakthrough cases (**Table 1, Table**
253 **2**). There was no simple relationship between the time elapsed since administration of
254 the second vaccination dose and the date of vaccination breakthrough. These 430
255 patients received either two doses of the Pfizer-BioNTech BNT162b2 ($n = 299$, 69%) or
256 Moderna mRNA-1273 ($n = 111$, 26%), or one dose of J&J/Janssen JNJ-78436735 ($n =$
257 20 , 5%) vaccine. This distribution reflects the majority use of BNT162b2 vaccination
258 doses in our health system. Compared to either Alpha or Delta patients, a significantly
259 greater percentage of patients with breakthrough cases was caused by the Omicron
260 VOC (49.9% compared to 3.2% and 24.1% for Alpha and Delta VOCs, respectively)
261 (**Table 1, Table 2**). We next analyzed individuals with breakthrough cases after
262 receiving a third (booster) dose of either the Pfizer-BioNTech BNT162b2 or Moderna
263 mRNA-1273 vaccine. We found that 85 (9.9%) of the 862 Omicron patients met this
264 criteria. Consistent with Omicron causing a significantly increased number of vaccine
265 breakthrough cases, it has been reported that this variant has reduced sensitivity to

266 antibody neutralization *in vitro*, likely in large part due to the extensive number of amino
267 acid and other structural changes occurring in Omicron spike protein¹⁰⁻²⁹.

268

269 An Omicron Sublineage With Spike Protein Polymorphism L452R

270

271 The L452R amino acid change in spike protein of SARS-CoV-2 has arisen by
272 convergent evolution in multiple genetic lineages throughout the course of the
273 pandemic, most notably in the Delta VOC. L452R is located in the receptor binding
274 domain of spike protein and has been associated with decreased antibody
275 neutralization, escape from cell mediated immunity, and increased affinity for the ACE2
276 receptor^{30, 31}. L452R was present in samples of Omicron collected in South Africa as
277 early as November 11, 2021. We found that all 43 specimens collected over the first
278 nine days after we identified Omicron in Houston Methodist patients had the 452R
279 amino acid replacement. Our first L452 isolate was collected on day 10. By day 16, over
280 half the Omicron isolates collected were L452, and the proportion of 452R isolates
281 continued to diminish. Among the 65,109 Omicron samples deposited in GISAID as of
282 28 December 2021, only 727 (1.1%) have the 452R amino acid replacement and over
283 half of these were from Houston Methodist patients. The initial high prevalence of
284 Omicron containing 452R in spike protein in our population likely represents a founder
285 effect of the original genotype introduced into Houston.

286

287 Spike-Gene Target-Failure Assay

288

289 To estimate Omicron variant frequency in patient samples not yet sequenced, we
290 performed the TaqPath COVID-19 Combo Kit assay (ThermoFisher) on 657 samples
291 collected from symptomatic patients between December 18, 2021 and December 22,
292 2021. In total, 604 (91.9%) of patient samples yielded a RT-PCR result with S-gene
293 target-failure indicative of the Omicron variant. These data are consistent with the
294 increasing frequency of new cases of COVID-19 caused by Omicron in our population
295 **(Figure 2).**

296

297 Lack of Omicron Variant BA.2 in Houston Methodist Samples

298

299 The BA.2 Omicron sublineage was first identified in November 2021 in Australia in a
300 patient who had traveled to South Africa ([https://github.com/cov-lineages/pango-](https://github.com/cov-lineages/pango-designation/issues/359)
301 [designation/issues/359](https://github.com/cov-lineages/pango-designation/issues/359); last accessed December 30, 2021). This sublineage does not
302 have the full set of polymorphisms characteristic of BA.1 (B.1.1.529) and also has
303 additional mutations unique to it ([https://github.com/cov-lineages/pango-](https://github.com/cov-lineages/pango-designation/issues/361)
304 [designation/issues/361](https://github.com/cov-lineages/pango-designation/issues/361); last accessed December 30, 2021). One important difference is
305 that sublineage BA.2 lacks the spike protein deletion at amino acid 69/70 which means
306 that it will not be detected by the SGTF assay. We inspected all full genome sequences
307 present in our large database and this sublineage was not present. This includes all
308 specimens taken from symptomatic patients or asymptomatic individuals. Thus, it is
309 likely that routine use of an SGTF assay in our population will identify patients infected
310 with Omicron.

311

312 **Discussion**

313

314 In this work, we describe information relevant to the surging Omicron wave in
315 metropolitan Houston. In three weeks, Omicron was first identified in our population and
316 rapidly increased to cause 90% of all new COVID-19 cases, with an estimated case
317 doubling time of 2.2 days. The study was based on genome sequence analysis of 862
318 Omicron samples taken from socioeconomically, geographically, and ethnically diverse
319 symptomatic patients. Several key findings were made, including (i) the Omicron VOC
320 rapidly increased as a cause of COVID-19 and spread throughout the metroplex in an
321 unusually short period of time, far faster than any other SARS-CoV-2 variant; (ii)
322 Omicron caused significantly more vaccine breakthrough cases than the Alpha or Delta
323 VOCs; (iii) Omicron patients were significantly younger than Alpha or Delta patients; (iv)
324 significantly fewer Omicron patients required hospitalization compared to Alpha and
325 Delta patients; (v) the median length of stay for hospitalized Omicron patients was
326 significantly shorter than for Alpha and Delta patients, and consistent with this
327 observation, the maximum respiratory support required for Omicron patients was
328 significantly less than for Alpha or Delta patients. Our findings are largely consistent
329 with many aspects of Omicron data reported from the UK, South Africa, and Canada⁷⁻⁹,
330 ^{32, 33} and are consistent with animal infection model data suggesting that Omicron
331 causes less severe disease in mice and hamsters^{34, 35}. This study was facilitated by a
332 comprehensive and integrated population genomics and epidemiology project²⁻⁶
333 implemented at the end of February, 2020, when the initial COVID-19 case was
334 diagnosed in the Houston Methodist healthcare system.

335 Because we sequence the genome of approximately 90% of SARS-CoV-2
336 causing COVID-19 in our diverse Houston Methodist patient population, and have done
337 so for almost two years, this means we are continuously monitoring the composition of
338 this virus in a major US metroplex. This affords us the opportunity to rapidly assess
339 changes in SARS-CoV-2 population genomic structure in the fourth largest city in the
340 US. However, our study has several limitations. Although we sequenced the genomes
341 of SARS-CoV-2 causing 90% of all Houston Methodist COVID-19 cases in the study
342 period, this sample represents only approximately 5% of cases reported in the
343 metropolitan region. Our patient population will underrepresent some demographic
344 groups, for example homeless individuals and pediatric patients. The samples
345 sequenced in this study were obtained from symptomatic individuals, which means that
346 it is possible that we failed to identify Omicron subvariants or features preferentially
347 represented in asymptomatic individuals.

348 In the aggregate, our data add critical new information to features of Omicron
349 genomic epidemiology and patient characteristics in the US. Further, the present study
350 highlights the importance of analyzing SARS-CoV-2 genome data integrated with
351 patient metadata and stresses the need to continue to do this in near-real time as the
352 Omicron surge continues, the virus evolves, and new variants with potentially altered
353 fitness and biomedically relevant phenotypes are generated. Analyses of this type are
354 also important in the context of vaccine formulation and long COVID, an increasing
355 health and economic problem globally. Finally, the strategy we have used in this and
356 previous studies²⁻⁶ are readily applicable to future infectious diseases problems that
357 warrant special attention.

358

359 **Acknowledgments**

360

361 We thank Drs. Marc Boom and Dirk Sostman for their ongoing support, and Dr. Sasha
362 M. Pejerrey for editorial contributions. The research was supported by the Houston
363 Methodist Academic Institute Infectious Diseases Fund and many generous Houston
364 philanthropists. The funders had no role in the design and conduct of the study;
365 collection, management, analysis, and interpretation of the data; preparation, review, or
366 approval of the manuscript; and decision to submit the manuscript for publication.

367

368 We declare that we have no conflict of interest.

369

370

371 **Author Contributions**

372

373 P.A.C., R.J.O., S.W.L., and J.M.M. had full access to all study data and take
374 responsibility for the integrity of the data and the accuracy of the data analysis; concept
375 and design by J.M.M., P.A.C., R.J.O., and S.W.L; data acquisition, analysis, or
376 interpretation by all authors; drafting of the manuscript by all authors; statistical analysis
377 by P.A.C.; funding obtained by J.M.M. and J.J.D.; and overall supervision by J.M.M.
378 P.A.C., R.J.O., and S.W.L. contributed equally and are co-first authors.

379

380

381 **References**

- 382 [1] Dhar MS, Marwal R, Radhakrishnan V, Ponnusamy K, Jolly B, Bhojar RC, Fatihi S, Datta M,
383 Singh P, Sharma U, Ujjainia R, Naushin S, Bhateja N, Divakar MK, Sardana V, Singh MK, Imran M,
384 Senthivel V, Maurya R, Jha N, Mehta P, Rophina M, Arvinden V, Chaudhary U, Thukral L, Pandey
385 R, Dash D, Faruq M, Lall H, Gogia H, Madan P, Kulkarni S, Chauhan H, Sengupta S, Kabra S,
386 Consortium TIS-C-G, Singh SK, Agrawal A, Rakshit P: Genomic characterization and
387 Epidemiology of an emerging SARS-CoV-2 variant in Delhi, India. medRxiv
388 2021:2021.06.02.21258076.
- 389 [2] Long SW, Olsen RJ, Christensen PA, Bernard DW, Davis JJ, Shukla M, Nguyen M, Saavedra
390 MO, Yerramilli P, Pruitt L, Subedi S, Kuo HC, Hendrickson H, Eskandari G, Nguyen HAT, Long JH,
391 Kumaraswami M, Goike J, Boutz D, Gollihar J, McLellan JS, Chou CW, Javanmardi K, Finkelstein
392 IJ, Musser JM: Molecular Architecture of Early Dissemination and Massive Second Wave of the
393 SARS-CoV-2 Virus in a Major Metropolitan Area. mBio 2020, 11.
- 394 [3] Musser JM, Olsen RJ, Christensen PA, Long SW, Subedi S, Davis JJ, Gollihar J: Rapid,
395 widespread, and preferential increase of SARS-CoV-2 B.1.1.7 variant in Houston, TX, revealed by
396 8,857 genome sequences. medRxiv 2021:2021.03.16.21253753.
- 397 [4] Olsen RJ, Christensen PA, Long SW, Subedi S, Hodjat P, Olson R, Nguyen M, Davis JJ,
398 Yerramilli P, Saavedra MO, Pruitt L, Reppond K, Shyer MN, Cambric J, Gadd R, Thakur RM,
399 Batajoo A, Finkelstein IJ, Gollihar J, Musser JM: Trajectory of Growth of Severe Acute
400 Respiratory (SARS-CoV-2) Syndrome Coronavirus 2 Variants in Houston, Texas, January through
401 May 2021, Based on 12,476 Genome Sequences. Am J Pathol 2021.
- 402 [5] Long SW, Olsen RJ, Christensen PA, Subedi S, Olson R, Davis JJ, Saavedra MO, Yerramilli P,
403 Pruitt L, Reppond K, Shyer MN, Cambric J, Finkelstein IJ, Gollihar J, Musser JM: Sequence
404 Analysis of 20,453 SARS-CoV-2 Genomes from the Houston Metropolitan Area Identifies the
405 Emergence and Widespread Distribution of Multiple Isolates of All Major Variants of Concern.
406 Am J Pathol 2021.
- 407 [6] Christensen PA, Olsen RJ, Long SW, Subedi S, Davis JJ, Hodjat P, Walley DR, Kinskey JC,
408 Saavedra MO, Pruitt L, Reppond K, Shyer MN, Cambric J, Gadd R, Thakur RM, Batajoo A,
409 Mangham R, Pena S, Trinh T, Yerramilli P, Nguyen M, Olson R, Snehal R, Gollihar J, Musser JM:
410 Delta Variants of SARS-CoV-2 Cause Significantly Increased Vaccine Breakthrough COVID-19
411 Cases in Houston, Texas. Am J Pathol 2021.
- 412 [7] Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Lessells RJ, Giandhari J, Wolter N,
413 Everatt J, Rambaut A, Althaus C, Wilkinson E, Mendes A, Strydom A, Davids M, Mayaphi S,
414 Gaseitsiwe S, Choga WT, Maruapula D, Zuze B, Radibe B, Koopile L, Shapiro R, Lockman S,
415 Mbulawa MB, Mphoyakgosi T, Smith-Lawrence P, Mosepele M, Matshaba M, Masupu K, Chand
416 M, Joseph C, Kuate-Lere L, Lesetedi-Mafoko O, Moruisi K, Scott L, Stevens W, Wibmer CK,
417 Mnguni A, Ismail A, Mahlangu B, Martin DP, Hill V, Colquhoun R, Motsaledi MS, San JE, Ntuli
418 N, Motsatsi G, Pillay S, Mohale T, Ramphal U, Naidoo Y, Tebeila N, Giovanetti M, Mlisana K,
419 Williamson C, Hsiao N-y, Msomi N, Mahlakwane K, Engelbrecht S, Maponga T, Preiser W,
420 Makatini Z, Laguda-Akingba O, Singh L, Anyaneji UJ, Moir M, Wyk Sv, Tshiabuila D, Ramphal Y,
421 Maharaj A, Pond S, Lucaci AG, Weaver S, Boni MF, Deforche K, Subramoney K, Hardie D, Marais
422 G, Doolabh D, Joseph R, Mbhele N, Olubayo L, Iranzadeh A, Zarebski AE, Tsui J, Kraemer MU,
423 Pybus OG, Goedhals D, Bester PA, Nyaga MM, Mwangi PN, Glass A, Treurnicht F, Venter M,

- 424 Bhiman JN, von Gottberg A, de Oliveira T: Rapid epidemic expansion of the SARS-CoV-2
425 Omicron variant in southern Africa. medRxiv 2021:2021.12.19.21268028.
- 426 [8] Elliott P, Bodinier B, Eales O, Wang H, Haw D, Elliott J, Whitaker M, Jonnerby J, Tang D,
427 Walters CE, Atchison C, Diggle PJ, Page AJ, Trotter AJ, Ashby D, Barclay W, Taylor G, Ward H,
428 Darzi A, Cooke GS, Chadeau-Hyam M, Donnelly CA: Rapid increase in Omicron infections in
429 England during December 2021: REACT-1 study. medRxiv 2021:2021.12.22.21268252.
- 430 [9] Sheikh AK, Steven; Woolhouse, Mark; McMenam, Jim; Robertson, Chris. : Severity of
431 Omicron variant of concern and vaccine effectiveness against symptomatic disease: national
432 cohort with nested test negative design study in Scotland. The University of Edinburgh 2021.
- 433 [10] Meng B, Ferreira I, Abdullahi A, Kemp SA, Goonawardane N, Papa G, Fatihi S, Charles O,
434 Collier D, Collaboration C-NBC-, Consortium TGtPJ, Choi J, Hyeon Lee J, Mlcochova P, James L,
435 Doffinger R, Thukral L, Sato K, Gupta RK: SARS-CoV-2 Omicron spike mediated immune escape,
436 infectivity and cell-cell fusion. bioRxiv 2021:2021.12.17.473248.
- 437 [11] Zeng C, Evans JP, Qu P, Faraone J, Zheng Y-M, Carlin C, Bednash JS, Zhou T, Lozanski G,
438 Mallampalli R, Saif LJ, Oltz EM, Mohler P, Xu K, Gumina RJ, Liu S-L: Neutralization and Stability of
439 SARS-CoV-2 Omicron Variant. bioRxiv 2021:2021.12.16.472934.
- 440 [12] Jacobsen H, Strengert M, Maass H, Ynga Durand MA, Kessel B, Harries M, Rand U, Abassi L,
441 Kim Y, Lueddecke T, Hernandez P, Ortmann J, Heise J-K, Castell S, Gornyk D, Gloeckner S,
442 Melhorn V, Lange B, Dulovic A, Haering J, Junker D, Schneiderhan-Marra N, Poehlmann S,
443 Hoffmann M, Krause G, Cicin-Sain L: Diminished neutralization responses towards SARS-CoV-2
444 Omicron VoC after mRNA or vector-based COVID-19 vaccinations. medRxiv
445 2021:2021.12.21.21267898.
- 446 [13] Eggink D, Andeweg SP, Vennema H, van Maarseveen N, Vermaas K, Vlaemynck B, Schepers
447 R, van Gageldonk-Lafeber AB, van den Hof S, Reusken CBEM, Knol MJ: Increased risk of
448 infection with SARS-CoV-2 Omicron compared to Delta in vaccinated and previously infected
449 individuals, the Netherlands, 22 November to 19 December 2021. medRxiv
450 2021:2021.12.20.21268121.
- 451 [14] Edara V-V, Manning KE, Ellis M, Lai L, Moore KM, Foster SL, Floyd K, Davis-Gardner ME,
452 Mantus G, Nyhoff LE, Bechnack S, Alaaeddine G, Naji A, Samaha H, Lee M, Bristow L, Hussaini L,
453 Ciric CR, Nguyen P-V, Gagne M, Roberts-Torres J, Henry AR, Godbole S, Grakoui A, Sexton M,
454 Piantadosi A, Waggoner JJ, Douek DC, Anderson EJ, Roupheal N, Wrammert J, Suthar MS:
455 mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-
456 CoV-2 Omicron variant. bioRxiv 2021:2021.12.20.473557.
- 457 [15] Zou j, Xia H, Xie X, Kurhade C, Machado RR, Weaver SC, Ren P, Shi P-Y: Neutralization
458 against Omicron SARS-CoV-2 from previous non-Omicron infection. bioRxiv
459 2021:2021.12.20.473584.
- 460 [16] Ikemura N, Hoshino A, Higuchi Y, Taminishi S, Inaba T, Matoba S: SARS-CoV-2 Omicron
461 variant escapes neutralization by vaccinated and convalescent sera and therapeutic monoclonal
462 antibodies. medRxiv 2021:2021.12.13.21267761.
- 463 [17] Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, Liu X, Lambe T, Crook D,
464 Stuart DI, Mongkolsapaya J, Nguyen-Van-Tam JS, Snape MD, Sreaton GR, group tC-Cs: Reduced
465 neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum. medRxiv
466 2021:2021.12.10.21267534.

- 467 [18] Cameroni E, Saliba C, Bowen JE, Rosen LE, Culap K, Pinto D, De Marco A, Zepeda SK, di Iulio
468 J, Zatta F, Kaiser H, Noack J, Farhat N, Czudnochowski N, Havenar-Daughton C, Sprouse KR,
469 Dillen JR, Powell AE, Chen A, Maher C, Yin L, Sun D, Soriaga L, Gustafsson C, Franko NM, Logue J,
470 Iqbal NT, Mazzitelli I, Geffner J, Grifantini R, Chu H, Gori A, Riva A, Giannini O, Ceschi A, Ferrari
471 P, Franzetti-Pellanda A, Garzoni C, Hebner C, Purcell LA, Piccoli L, Pizzuto MS, Walls AC, Telenti
472 A, Virgin HW, Lanzavecchia A, Veessler D, Snell G, Corti D: Broadly neutralizing antibodies
473 overcome SARS-CoV-2 Omicron antigenic shift. *bioRxiv* 2021:2021.12.12.472269.
- 474 [19] Liu L, Iketani S, Guo Y, Chan JF-W, Wang M, Liu L, Luo Y, Chu H, Huang Y, Nair MS, Yu J, Chik
475 KK-H, Yuen TT-T, Yoon C, To KK-W, Chen H, Yin MT, Sobieszczyk ME, Huang Y, Wang HH, Sheng
476 Z, Yuen K-Y, Ho DD: Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-
477 2. *bioRxiv* 2021:2021.12.14.472719.
- 478 [20] Planas D, Saunders N, Maes P, Benhassine FG, Planchais C, Porrot F, Staropoli I, Lemoine F,
479 Pere H, Veyer D, Puech J, Rodary J, Bolland WH, Buchrieser J, Baele G, Dellicour S, Raymenants
480 J, Gorissen S, Geenen C, Vanmechelen B, Wawina T, Marti J, Cuypers L, Seve A, Hocqueloux L,
481 Prazuck T, Lorie ES, REY F, Bruel T, Mouquet H, Andre E, Schwartz O: Considerable escape of
482 SARS-CoV-2 variant Omicron to antibody neutralization. *bioRxiv* 2021:2021.12.14.472630.
- 483 [21] Andrews N, Stowe J, Kirsebom F, Toffa S, Ricketts T, Gallagher E, Gower C, Kall M, Groves
484 N, O'Connell A-M, Simons D, Blomquist PB, Zaidi A, Nash S, Aziz NIBA, Thelwall S, Dabrera G,
485 Myers R, Amirthalingam G, Gharbia S, Barrett JC, Elson R, Ladhani SN, Ferguson N, Zambon M,
486 Campbell CN, Brown K, Hopkins S, Chand M, Ramsay M, Bernal JL: Effectiveness of COVID-19
487 vaccines against the Omicron (B.1.1.529) variant of concern. *medRxiv*
488 2021:2021.12.14.21267615.
- 489 [22] Yu X, Wei D, Xu W, Li Y, Li X, Zhang X, Qu J, Yang Z, Chen E: Reduced sensitivity of SARS-
490 CoV-2 Omicron variant to booster-enhanced neutralization. *medRxiv*
491 2021:2021.12.17.21267961.
- 492 [23] Cele S, Jackson L, Khan K, Houry DS, Moyo-Gwete T, Tegally H, Scheepers C, Amoako D,
493 Karim F, Bernstein M, Lustig G, Archary D, Smith M, Ganga Y, Jule Z, Reedoy K, Cromer D, San JE,
494 Hwa S-H, Giandhari J, Blackburn JM, Gosnell BI, Karim SSA, Hanekom W, NGS-SA, Team C-K, von
495 Gottberg A, Bhiman J, Lessells RJ, Moosa M-YS, Davenport MP, de Oliveira T, Moore PL, Sigal A:
496 SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited
497 neutralization and requires ACE2 for infection. *medRxiv* 2021:2021.12.08.21267417.
- 498 [24] Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An R, Wang J,
499 Wang Y, Niu X, Yang S, Liang H, Sun H, Li T, Yu Y, Cui Q, Liu S, Yang X, Du S, Zhang Z, Hao X, Shao
500 F, Jin R, Wang X, Xiao J, Wang Y, Xie XS: B.1.1.529 escapes the majority of SARS-CoV-2
501 neutralizing antibodies of diverse epitopes. *bioRxiv* 2021:2021.12.07.470392.
- 502 [25] Hansen CH, Schelde AB, Moustsen-Helms IR, Emborg H-D, Krause TG, Moelbak K,
503 Valentiner-Branth P, Institut TIDPGaSS: Vaccine effectiveness against SARS-CoV-2 infection with
504 the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273
505 vaccination series: A Danish cohort study. *medRxiv* 2021:2021.12.20.21267966.
- 506 [26] Syed AM, Ciling A, Khalid MM, Sreekumar B, Kumar GR, Silva I, Milbes B, Kojima N, Hess V,
507 Shacreaw M, Lopez L, Brobeck M, Turner F, Spraggon L, Taha TY, Tabata T, Chen IP, Ott M,
508 Doudna JA: Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-
509 CoV-2 virus-like particles. *medRxiv* 2021:2021.12.20.21268048.

- 510 [27] Sheward DJ, Kim C, Ehling RA, Pankow A, Castro Dopico X, Martin DP, Reddy ST, Dillner J,
511 Karlsson Hedestam GB, Albert J, Murrell B: Variable loss of antibody potency against SARS-CoV-
512 2 B.1.1.529 (Omicron). *bioRxiv* 2021:2021.12.19.473354.
- 513 [28] Haveri A, Solastie A, Ekström N, Österlund P, Nohynek H, Nieminen T, Palmu AA, Melin M:
514 Neutralizing antibodies to SARS-CoV-2 Omicron variant after 3rd mRNA vaccination in health
515 care workers and elderly subjects and response to a single dose in previously infected adults.
516 *medRxiv* 2021:2021.12.22.21268273.
- 517 [29] Arien KK, Heyndrickx L, Michiels J, Vereecken K, Van Lent K, Coppens S, Pannus P, Martens
518 GA, Van Esbroeck M, Goossens ME, Marchant A, Bartholomeeusen K, Desombere I: Three doses
519 of the BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2
520 B.1.1.529 (Omicron) variant of concern. *medRxiv* 2021:2021.12.23.21268316.
- 521 [30] Motozono C, Toyoda M, Zahradnik J, Saito A, Nasser H, Tan TS, Ngare I, Kimura I, Uriu K,
522 Kosugi Y, Yue Y, Shimizu R, Ito J, Torii S, Yonekawa A, Shimono N, Nagasaki Y, Minami R, Toya T,
523 Sekiya N, Fukuhara T, Matsuura Y, Schreiber G, Ikeda T, Nakagawa S, Ueno T, Sato K: SARS-CoV-
524 2 spike L452R variant evades cellular immunity and increases infectivity. *Cell Host Microbe*
525 2021, 29:1124-36.e11.
- 526 [31] Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, Zhao C, Zhang Q, Liu H, Nie L, Qin H, Wang M, Lu Q,
527 Li X, Sun Q, Liu J, Zhang L, Li X, Huang W, Wang Y: The Impact of Mutations in SARS-CoV-2 Spike
528 on Viral Infectivity and Antigenicity. *Cell* 2020, 182:1284-94 e9.
- 529 [32] Ulloa AC, Buchan SA, Daneman N, Brown KA: Early estimates of SARS-CoV-2 Omicron
530 variant severity based on a matched cohort study, Ontario, Canada. *medRxiv*
531 2021:2021.12.24.21268382.
- 532 [33] Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, Amoako DG, Everatt J,
533 Bhiman JN, Scheepers C, Tebeila N, Chiwandire N, du Plessis M, Govender N, Ismail A, Glass A,
534 Mlisana K, Stevens W, Treurnicht FK, Makatini Z, Hsiao N-y, Parboosing R, Wadula J, Hussey H,
535 Davies M-A, Boule A, von Gottberg A, Cohen C: Early assessment of the clinical severity of the
536 SARS-CoV-2 Omicron variant in South Africa. *medRxiv* 2021:2021.12.21.21268116.
- 537 [34] Bentley EG, Kirby A, Sharma P, Kipar A, Mega DF, Bramwell C, Penrice-Randal R, Prince T,
538 Brown JC, Zhou J, Sreaton GR, Barclay WS, Owen A, Hiscox JA, Stewart JP: SARS-CoV-2
539 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains
540 in a mouse model of severe COVID-19. *bioRxiv* 2021:2021.12.26.474085.
- 541 [35] Abdelnabi R, Foo CS, Zhang X, Lemmens V, Maes P, Slechten B, Raymenants J, André E,
542 Weynand B, Dallemier K, Neyts J: The omicron (B.1.1.529) SARS-CoV-2 variant of concern does
543 not readily infect Syrian hamsters. *bioRxiv* 2021:2021.12.24.474086.
- 544

545

546 **Figure Legends**

547

548 **Figure 1** Epidemiologic curve showing five COVID-19 disease waves in Houston
549 Methodist patients. Number of new COVID-19 cases (y-axis) totals are shown as a +/-
550 three-day moving average. Each of the five waves is shown in a different color. The first
551 and second waves were composed of a heterogenous array of SARS-CoV-2 genotypes.
552 The Alpha VOC shown in the third wave, the Delta VOC shown in the fourth, and the
553 Omicron VOC shown in the fifth wave indicate their numeric prominence in those
554 waves. The data should not be interpreted to mean that all cases in the third, fourth, and
555 fifth waves were caused by Alpha, Delta, and Omicron VOCs, respectively. Rather, they
556 are the dominant VOCs causing disease in Houston Methodist system patients in those
557 waves. The fifth wave shown includes data through December 18, 2021. The figure was
558 generated with Tableau version 2021.2.7 (Tableau Software, LLC, Seattle, WA), and is
559 a modified version of one presented recently⁶. The curve is essentially superimposable
560 on COVID-19 activity in all metropolitan Houston, Texas.

561

562 **Figure 2** Increase in Omicron frequency over time and distribution in metropolitan
563 Houston. The study time frame was November 27, 2021 through December 18, 2021.
564 **A:** Omicron logistic growth model. The estimated case doubling time is 2.2 days. **B:**
565 Cumulative increase in Omicron during the study period; y-axis is the cumulative
566 number of new COVID-19 Omicron cases. At the end of the study period, Omicron
567 caused 90% of all COVID-19 cases. **C – E:** Geospatial distribution of Omicron based on
568 home address zip code for each patient. **B:** November 27 – December 3; **C:** November

569 27 – December 10; **D**: November 27 – December 18. Note differences in heat map
570 scale for each panel. Figures were generated using Tableau version 2021.2.7. (Tableau
571 Software, LLC, Seattle, WA).

572 **Table 1. Summary of pertinent patient metadata for 4021 unique patients infected**
 573 **with Omicron or Alpha variants.**

	Omicron Variant	Alpha Variant	Total	Statistical Analysis
No. (%) with data	862 (21.4%)	3159 (78.6%)	4021	
Patient Characteristics				
Median Age (Years)	38.9	50.0	47.6	$P < 0.0001$ Mann-Whitney
Female	505 (58.6%)	1623 (51.4%)	2128 (52.9%)	$P = 0.0002$ Fisher's exact test
Male	357 (41.4%)	1536 (48.6%)	1893 (47.1%)	
Ethnicity				
Caucasian	256 (29.7%)	1242 (39.3%)	1498 (37.3%)	$P < 0.0001$ Chi-square
Hispanic or Latino	156 (18.1%)	945 (29.9%)	1101 (27.4%)	
Black	368 (42.7%)	732 (23.2%)	1100 (27.4%)	
Asian	34 (3.9%)	123 (3.9%)	157 (3.9%)	
Other	3 (0.3%)	32 (1.0%)	35 (0.9%)	
Unavailable	45 (5.2%)	85 (2.7%)	130 (3.2%)	
BMI				
Median BMI	28.7	30.5	30.2	$P < 0.0001$ Mann-Whitney
Admission Data				
Admitted	134 (15.5%)	1721 (54.5%)	1855 (46.1%)	$P < 0.0001$ Fisher's exact test Odds Ratio: 0.154 (95% CI 0.126- 0.187)
Not Admitted	728 (84.5%)	1438 (45.5%)	2166 (53.9%)	
Median LOS (Days) (Discharged patients only)	2.8	5.1	5.0	$P < 0.0001$ Mann-Whitney
Max Respiratory Support				
ECMO	1 (0.7%)	7 (0.4%)	8 (0.4%)	$P < 0.0001$ Chi-square
Mechanical Ventilation	6 (4.5%)	144 (8.4%)	150 (8.1%)	

Non-Invasive Ventilation	9 (6.7%)	164 (9.5%)	173 (9.3%)	
High Flow Oxygen	12 (9.0%)	364 (21.2%)	376 (20.3%)	
Low Flow Oxygen	42 (31.3%)	722 (42.0%)	764 (41.2%)	
Room Air	64 (47.8%)	320 (18.6%)	384 (20.7%)	
Mortality				
Alive	854 (99.1%)	2989 (94.6%)	3843 (95.6%)	$P < 0.0001$
Deceased	8 (0.9%)	170 (5.4%)	178 (4.4%)	Fisher's exact test
				Odds Ratio: 0.165 (95% CI 0.081- 0.336)
Median PCR Cycle Threshold				
Abbott Alinity	19.5 n=327	22.4 n=1051	n=1378	$P < 0.0001$ Mann-Whitney
Hologic Panther	22.1 n=60	24.2 n=359	n=419	$P = .0991$ Mann-Whitney
Vaccine				
Not Fully Vaccinated	432 (50.1%)	3058 (96.8%)	3490 (86.8%)	$P < 0.0001$
Yes Fully Vaccinated	430 (49.9%)	101 (3.2%)	531 (13.2%)	Fisher's exact test
				Odds Ratio: 30.137 (95% CI 23.731- 38.273)

574 BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of stay

575 **Table 2. Summary of pertinent patient metadata for 16,501 unique patients**
 576 **infected with Omicron or Delta variants.**


	Omicron Variant	Delta Variant	Total	Statistical Analysis
No. (%) with data	862 (5.2%)	15639 (94.8%)	16501	
Patient Characteristics				
Median Age (Years)	38.9	48.2	47.7	$P < 0.0001$ Mann-Whitney
Female	505 (58.6%)	8083 (51.7%)	8588 (52.0%)	$P = 0.0001$ Fisher's exact test
Male	357 (41.4%)	7556 (48.3%)	7913 (48.0%)	
Ethnicity				
Caucasian	256 (29.7%)	6853 (43.8%)	7109 (43.1%)	$P < 0.0001$ Chi-square
Hispanic or Latino	156 (18.1%)	4150 (26.5%)	4306 (26.1%)	
Black	368 (42.7%)	3445 (22.0%)	3813 (23.1%)	
Asian	34 (3.9%)	526 (3.4%)	560 (3.4%)	
Other	3 (0.3%)	112 (0.7%)	115 (0.7%)	
Unavailable	45 (5.2%)	553 (3.5%)	598 (3.6%)	
BMI				
Median BMI	28.7	29.5	29.5	$P = 0.0011$ Mann-Whitney
Admission Data				
Admitted	134 (15.5%)	6730 (43.0%)	6864 (41.6%)	$P < 0.0001$ Fisher's exact test Odds Ratio: 0.244 (95% CI 0.202- 0.294)
Not Admitted	728 (84.5%)	8909 (57.0%)	9637 (58.4%)	
Median LOS (Days) (Discharged patients only)	2.8	5.4	5.3	$P < 0.0001$ Mann-Whitney
Max Respiratory Support				
ECMO	1 (0.7%)	19 (0.3%)	20 (0.3%)	$P < 0.0001$ Chi-square
Mechanical Ventilation	6 (4.5%)	720 (10.7%)	726 (10.6%)	

Non-Invasive Ventilation	9 (6.7%)	638 (9.5%)	647 (9.4%)	
High Flow Oxygen	12 (9.0%)	1778 (26.4%)	1790 (26.1%)	
Low Flow Oxygen	42 (31.3%)	2274 (33.8%)	2316 (33.7%)	
Room Air	64 (47.8%)	1301 (19.3%)	1365 (19.9%)	
Mortality				
Alive	854 (99.1%)	14815 (94.7%)	15669 (95.0%)	$P < 0.0001$
Deceased	8 (0.9%)	824 (5.3%)	832 (5.0%)	Fisher's exact test
				Odds Ratio: 0.168 (95% CI 0.084- 0.339)
Median PCR Cycle Threshold				
Abbott Alinity	19.5 n=327	21.4 n=5081	n=5408	$P < 0.0001$ Mann-Whitney
Hologic Panther	22.1 n=60	22.7 n=1291	n=1351	$P = .9524$ Mann-Whitney
Vaccine				
No vaccine	403 (46.8%)	11374 (72.7%)	11777 (71.4%)	$P < 0.0001$
>7 days past 1st Vaccine	29 (3.4%)	489 (3.1%)	518 (3.1%)	Chi-square
>14 days past 2nd Vaccine	345 (40.0%)	3641 (23.3%)	3986 (24.2%)	
>14 days past 3rd Vaccine	85 (9.9%)	135 (0.9%)	220 (1.3%)	

577 BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of stay


578

579 **Figure 1.**



580

581 **Figure 2.**



582